OSTX (42) RNXT (31) FBIO (39) MNOV (30) ⌘ Pro Terminal →

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) — RQD Stock Rating Cockpit

$1.30 -9.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.28

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $67.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZYBT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZYBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Zhengye Biotechnology Holding Limited (Class A) (NASDAQ: ZYBT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.30 (-9.09% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZYBT ranks #531 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZYBT compare to OSTX and RNXT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYBT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 20.5%, and ROIC of -22.3%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZYBT?

▼

Per ZYBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001975641), Zhengye Biotechnology Holding Limited (Class A) generated $16.6M in revenue (-34.8% YoY), -$10.0M in net income, and $1.8M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.28 (-1.83%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 10.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZYBT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY ZYBT SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 10.6% FCF Margin ($1.8M FCF) & 20.5% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (20% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.73-19.1% Next Q

Q2 (-2Q)

Grade D$1.40+7.1% Next Q

Q3 (-1Q)

Grade D$1.50-13.3% Next Q

Current

Grade D-$1.30-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZYBT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZYBT currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.48) and Max Pain ($1.37) forces dealer call-delta covering toward $8.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZYBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZYBT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

43.130 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

1.90>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE9% OF RANGE

L: $1$1.30H: $8

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ZYBT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

-22.3% ROIC with 20.5% gross margin and 2.61% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (35)

Altman-Z 1.90 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (38)

15/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like ZYBT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZYBT)

✓Walkthrough of ZYBT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZYBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.30%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.17H $1.40L $1.17C $1.30VOL 122.9K

RES: $3.19SUP: $1.08SMA50: $1.48SMA200: $1.16

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZYBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZYBT Butterfly Map → + Track ZYBT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -34.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZYBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZYBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZYBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZYBT)

Health Care Rank #531 of 1016 ⚔️ OSTX vs ZYBT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZYBT vs. OSTX, RNXT, FBIO, MNOV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zhengye Biotechnology Holding Limited (Class A) (ZYBT) ranks #531 by composite RQD confidence (40/100, grade D-) and #710 by equity capitalization ($67.8M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ZYBT at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZYBT ACTIVE Zhengye Biotechnology Holding Limited (Class A)	D-	40/100	—	20.5%	-22.3%	-9.09%	$67.8M	Benchmark Subject
OSTX OS Therapies Incorporated	D-	42/100	—	—	-35.0%	-4.61%	$67.6M	/ostx-vs-zybt →
RNXT RenovoRx Inc.	E	31/100	—	70.9%	-35.0%	-10.74%	$67.2M	/rnxt-vs-zybt →
FBIO Fortress Biotech Inc.	D-	39/100	—	66.9%	-35.0%	-4.00%	$66.7M	/fbio-vs-zybt →
MNOV Medicinova Inc	E	30/100	5.7x	—	-35.0%	0.00%	$68.9M	/mnov-vs-zybt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001975641

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zhengye Biotechnology Holding Limited (Class A) (ZYBT) reported GAAP revenue of $16.6M (-34.8% vs. FY2024 revenue of $25.5M ) , GAAP net income of -$10.0M, operating cash flow of $1.9M, and free cash flow of $1.8M (-53.0% YoY). On the balance sheet, ZYBT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 1.90, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.6M	-$10.0M	$1.9M	$1.8M	$62.4M	—
FY2024 (FY)	2024-12-31	$25.5M	$1.6M	$5.6M	$3.8M	$67.6M	$658.0K

3. ZYBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZYBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ZYBT compare to OSTX and RNXT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ZYBT?

Where is ZYBT trading relative to its 50-day, 200-day, and 52-week technical levels?

ZYBT last traded at $1.30 (-9.09% on volume of 122,945 shares), positioning the stock -12.16% below its 50-day simple moving average ($1.48) and +12.07% above its 200-day simple moving average ($1.16). Across its 52-week range of $0.62 to $8.01, ZYBT sits at the 9.2% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.14 to $1.46).

ZYBT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ZYBT stock right now?

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) currently earns a Roarable Rating of D- (Sell — SELL) with 40/100 RQD Confidence. Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.

What is ZYBT's 12-month price target and RQD AI Jury consensus?

ZYBT's 12-month base price target is $1.19 (range $0.93 to $8.41), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ZYBT RQD Cockpit ZYBT 12M Forecast ZYBT Earnings & Move ZYBT Dividends & DRIP ZYBT Insiders & 13F ZYBT Whale Options ZYBT Profit Sankey ZYBT News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ZYBT — Zhengye Biotechnology Holding Limited (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:45:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ZYBT scores 40 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 10 / 20. Per the RQD rating, this reflects ROIC of -22.3% and an FCF yield of 2.61%. A negative ROIC indicates the business is not currently earning returns on invested capital, which weighs heavily on this pillar even though the FCF yield is positive.
Whale 13F Flow: 8 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. No holder data is supplied in the source data, so the specific drivers of this score cannot be traced further.
Insider Conviction: 7 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. Underlying transaction detail is not supplied in the source data.
Macro Regime Fit: 8 / 20. Per the RQD rating, this reflects a beta of 1.0 and sector sensitivity.
Forensic Balance Sheet: 7 / 20. Per the RQD rating, this reflects an Altman Z-Score of 1.9, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5.

For a prospective investor evaluating the stock today, the rating points to a company with negative operating and net margins, negative ROIC, and a weak forensic profile. The 52-week range of $0.62 to $8.01 and the current price of $1.3 reflect a very wide trading band, and the share price change of -9.09% is consistent with the pressure the rating describes. The upside case rests on the positive FCF yield and the stock's low absolute price, but the source data does not establish a path to earnings or returns that would offset the weaknesses across the pillars.

Business

Per the profile section, Zhengye Biotechnology Holding Limited (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The source data does not describe its products, customers, or revenue model. Per the SEC financials, the company reported revenue of $16.6M for FY 2025 and $25.5M for FY 2024.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$16.6M	$-10.1M	$-10.0M	N/A	$1.8M	N/A	N/A
FY 2024	$25.5M	$2.3M	$1.6M	N/A	$3.8M	$2.5M	$0.7M

Per the SEC financials, the company moved from positive operating income of $2.3M and net income of $1.6M in FY 2024 to operating and net losses of $-10.1M and $-10.0M in FY 2025, on lower revenue. Per the market data, gross margin is 20.5%, while operating and net margins are both -60%, and ROIC is -22.3%. Per the RQD rating, the Altman Z-Score is 1.9 and the Piotroski F-Score is 4/9. Per the RQD rating, Debt/Equity is 0.5. Per the SEC financials, FY 2025 cash and debt are not available in source data, so current balance sheet posture cannot be fully verified from the filings provided.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data.

Open Questions

What products and customers generate the FY 2025 revenue decline from $25.5M to $16.6M, and what drove the swing to operating losses?
What are FY 2025 cash and debt balances, given that both are listed as N/A in the SEC financials?
What is the source of the $0.62 to $8.01 trading range, and what events drove the share price change of -9.09%?
What are the company's pipeline, regulatory status, and any dependencies that would explain the Pharmaceutical Preparations classification?
Who holds the stock, and what do the insider and institutional flows reflected in the RQD pillar scores consist of?

ZYBT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zhengye Biotechnology Holding Limited (Class A) (ZYBT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZYBT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 104d ago

Zhengye Biotechnology Says No Material Events Behind Unusual Trading Activity (NASDAQ:ZYBT)

The company issued a statement after a sharp increase in trading volume, saying it is unaware of any undisclosed developments that would explain the recent market activity. Key Investor TakeawaysZhengye Biotechnology (NA

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 150d ago

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 210d ago

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 104d ago

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 88d ago

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 187d ago

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Yahoo Finance coverage on ZYBT stock catalysts, institutional flow, and earnings outlook.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 265d ago

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE TradingView • 7d ago

Zhengye Biotechnology Holding Limited Estimates – NASDAQ:ZYBT

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5QWEdnZ3VYSGZNRUVROVI2OVVSbVJVVXJjU25sa0toM3FTU0xSQUtSelE4bkkxdHh3UlRfVVhpbldoT1AwRzFPRndhbVFWa3hBUnZGX3FaY3F0dFZfeHpvNW9adXJGSGM3NE9veDNfelktSmZGRGZaTw?oc=5

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZYBT Bull vs. Bear Conversation Board — What's Your Call at $1.30?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZYBT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.14 (-12.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ZYBT (D- • RQD 40/100) a Buy at $1.30?

Welcome to the ZYBT (Zhengye Biotechnology Holding Limited (Class A)) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.09 (-16.2%)

Spot @ $1.30

Pump the brakes on ZYBT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ZYBT, but look at what you are paying: current EV/EBITDA multiples with 20.5% gross margins. Unless Zhengye Biotechnology Holding Limited (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.55 (+19.2%)

Spot @ $1.30

ZYBT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ZYBT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.30 (52-wk range $0.62 - $8.01), any beat on forward guidance forces shorts and underweight funds to chase.